PTEN PATTERSON UTI ENERGY INC Insider Trading

Patterson UTI COO sells 150,000 shares at $11.47; holdings drop to 421.5K (-26.2%)

James Michael Holcomb, EVP & Chief Operating Officer, sold 150,000 shares (150.0K shares) at $11.47 on 2026-05-28, reducing his post-transaction holdings to 421,523 shares (421.5K shares), a -26.2% reduction in his stake. The sale occurs against a backdrop of deteriorating company fundamentals: Patterson UTI reported a net loss of $-24,627,000.00 ($-24.6M) in its most recent full fiscal year, annual revenue declined -10.2% year-over-year, and the stock is currently -11.8% below its 52-week high. The substantial reduction in the COO's personal position, combined with the company's unprofitable state and negative revenue trajectory, warrants investor attention to near-term operational and strategic developments.

PTEN CEO sells $2.96M in shares as stock recovers from lows; company posts losses.

William Andrew Hendricks Jr., Patterson UTI Energy's President and CEO, executed a substantial sale of roughly a quarter-million shares worth nearly $3M, reducing his stake by over 8%. The timing is notable: the stock has recovered sharply from its lows and is now trading modestly below its recent highs, making this a disciplined take-profit rather than a panic exit. However, the move occurs against a backdrop of fundamental headwinds—the company is unprofitable with declining annual revenue and continued quarterly losses—which raises the question of whether the CEO sees limited upside at current valuations or is simply rebalancing after the recent bounce. The sale itself isn't necessarily bearish (insiders have every right to diversify), but paired with deteriorating earnings and a stock price that's rebounded significantly, it suggests caution at these levels rather than conviction in a turnaround.

Director Drummond sells 384k shares for $4.6M; stock up 20% in 30 days but company unprofitable with negative earnings.

Director Robert Wayne Drummond Jr. sold approximately 384,000 shares across two transactions in May, raising $4.6 million. This is notable because the stock has climbed significantly over the past month, yet Drummond chose to sell into that strength despite the company reporting negative earnings in both recent quarters. His own track record at this ticker is mixed: three of his four prior sales at Patterson UTI were well-timed, with the stock falling afterward, but one was poorly timed as shares rose. The company's fundamentals remain challenged—recent quarterly results show continued losses and revenue declining year-over-year—which may explain why Drummond is reducing exposure even as the stock price has recovered. This is a repeat seller; these are his 12th and 13th open-market sales in the past three years, suggesting a consistent pattern of trimming rather than accumulation.